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Summary: Trauma-induced multiple organ failure in sheep was prevented by aprotinin therapy.
Multiple organ failure was induced in 16 female merino sheep by initial haemorrhagic shock and intramedullary
femoral nailing (day 0), and 12 hourly injections of 0.75 μg/kg Escherichia coli endotoxin + 0.7 ml/kg zymosan-
activated plasma (days 1—5). In addition, the aprotinin group (n = 6) received simultaneous injections of 5 mg/kg
(35 695 KIU/kg) aprotinin, whereas ten animals did not receive aprotinin and served as the control group (n = 10).
Organ functions were monitored for a total of 11 days by measuring haemodynamic, cardio-respiratory and bio-
chemical quantities of blood, urine and epithelial lining fluid.
During the subsequent eleven day period, aprotinin induced a significant (*p < 0.05) reduction of the pathological
changes (development of multiple organ failure) seen in the control group. Thus, aprotinin prevented an alteration
of cardiac function (cardiac index for control/aprotinin groups at day 1: 6.5/6.2, and at day 10: 10.47/7.0*
1/min · m2), an impairment of lung function (mean pulmonary arterial pressure at day 1: 2.26/1.86, and at day 10:
3.83/2.13* kPa; epithelial lining fluid/plasma ratio of albumin concentrations as a direct marker of lung capillary
permeability damage at dayO: 0.18/0.16, and at day 10: 0.45/0.15*), a deterioration of liver function (plasma
sorbitol dehydrogenase at day 0: 7.9/7.6, and at day 10: 29.6/7.4* U/l), but not of renal function (creatinine clearance
at day 1: 91.4/66.1, and at day 10: 53.1/59.2 ml/min). Urinary aprotinin excretion increased up to day 3, then
decreased rapidly despite further aprotinin administration. As a non-specific marker of cell damage, plasma lactate
dehydrogenase indicated an aprotinin-induced organ protection (day 0: 501/409, and at day 10: 719/329* U/l).
The neutrophil count and the measured chemiluminescence of neutrophils from the blood and epithelial lining fluid
showed that aprotinin reduced the in vivo neutrophil activation, the alveolar neutrophil invasion, the production of
inflammatory mediators, and the production of reactive oxygen metabolites during the passage of the capillary-
interstitial-alveolar space by neutrophils.
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krein by aprotinin prevented systemic vasodilatation and
pulmonary hypertension (18).
Therefore, our aim was to evaluate whether inhibition
of the main target enzymes (plasmin, kallikrein) by
aprotinin in a trauma-induced sheep model of multiple
organ failure would improve organ functions and pre-
vent multiple organ failure development.
Materials and Methods
Animal preparat ion, haemodynamic and
cardio-respiratory measurements
All procedures were performed according to the German council's
guide for the care and use of laboratory animals of August 18, 1986
and were approved by the animal protection committee of the local
government (No. 93600).
Adult female merino sheep were used, weighing 25-30 kg. To
produce multiple organ failure, the animals were treated as pre-
viously described (9, 10). Briefly, at day 0 a venous catheter was
placed into the right jugular vein under local anaesthesia and blood
was drawn and anticoagulated with sodium citrate for basic mea-
surements. General anaesthesia was induced with 0.5 mg Atropin®
and 3.5 mg/kg body weight Pentobarbital® and was continued by
ventilation with halothane/nitrogen oxide/oxygen after intubation.
Further catheters were placed into the femoral vein and artery, a
Swan-Ganz thermodilution catheter (Baxter model 93 A-131-7F,
Edwards Critical Care Division, Irvine, CA, USA) was inserted via
an external jugular vein and advanced into the pulmonary artery.
Another catheter was located into the urinary bladder (Norta, Mod-
ell 10 - No. 9385, BDF Beiersdorf AG, Hamburg, Germany) and
connected with a collection tube.
Arterial, central venous, pulmonary arterial and pulmonary capil-
lary wedge pressure were recorded using pressure transducers
which were positioned at the level of the right atrium. Calibration
was done prior to each measurement. Cardiac index was measured
by the thermodilution method. In heparinized arterial and mixed
venous blood samples, acidity, carbon dioxide, oxygen tension, and
oxygen saturation were recorded using a blood gas analyser
(ABL2, Radiometer, Copenhagen, Denmark).
Alveolar-to-arterial oxygen pressure difference, right ventricular
stroke work index, pulmonary vascular resistance, and arterio-to-
venous oxygen pressure difference were calculated by standard for-
mulae from the quantities measured. Blood (anticoagulated with
sodium citrate) for biochemical measurements was drawn every
day in the morning before each treatment.
During the experiment the animals did not receive any further oper-
ative treatment and had free access to food and water. The animals
were observed for a total of 11 days and then sacrificed under
anaesthesia by infusion of 0.1 ml/kg T61 (Embutramid + Mebe-
zoniumiodide + Tetracin hydrochloride; Hoechst AG, Frankfurt,
Germany).
Bronchoalveolar lavage technique
Bronchoscopy and bronchoalveolar lavage were performed with a
fiberoptic bronchoscope (Olympus BF type l T 10, Olympus Cor-
poration of America, New Hyde Park, N. Y., USA) as previously
described (19). Under light anaesthesia (1.5 mg/kg thiopental so-
dium and subsequent injection of 2 mg/kg pentobarbital) the
bronchoalveolar lavage procedure was performed at days 0 (prior
to the induction of haemorrhagic shock), day 6, and day 10 before
each medication/treatment.
Haemorrhagic shock and intramedullary femoral
nai l ing
After bronchoscopy blood was drawn in 50 ml portions until the
mean arterial pressure was 6.7 kPa. This was maintained for 2
hours by fractional blood withdrawal. The total blood volume col-
lected was 450-600 ml (about 20 ml/kg). Then, a three-times vol-
ume of Ringer-lactatQ solution and 5 mg/kg aprotinin2) in a total
of 5 ml of saline were infused (aprotinin was given only in the
treatment group) until the mean arterial blood pressure reached a
normal level. This was followed by a closed intramedullary femo-
ral nailing procedure with a standard AO technique (20).
• ··
Administration of endotoxin and zymosan-activated
plasma
After overnight recovery, haemodynamic and cardio-respiratory
quantities were measured and blood was drawn (anticoagulated
with sodium citrate) for the biochemical measurements. Then, 0.7
ml/kg zymosan-activated autologous plasma + 0.75 μg/kg endo-
toxin were injected in 5 ml of saline simultaneously with 5 mg/kg
(= 35 695 KIU/kg) aprotinin in 5 ml of saline (aprotinin group;
η = 6) and without aprotinin (control group; η = 10). This admin-
istration was repeated every 12 hours for a total of 5 days, and
baseline measurements were performed every day in the morning
before each application.
Endotoxin, zymosan-activated plasma and aprotinin
preparations
Escherichia coli endotoxin (serotype 055:B5, Sigma Chemicals,
Deisenhofen, Germany) was dissolved in saline and applicated in
a total of 5 ml of saline to yield 0.75 μg/kg. For the production
of zymosan-activated plasma, 450 ml blood (anticoagulated with
sodium citrate) were withdrawn at day 0 and centrifuged for 10
min at 800 g and 22 °C. The plasma was then incubated with sterile
zymosan (3 mg/ml plasma) (zymosan A, Sigma Chemicals,
Deisenhofen, Germany; sterilized at 120 °C, 203 kPa absolute pres-
sure, 20 min) for 30 min at 30 °C with agitation. After centrifuga-
tion for 15 min and 800 g at 22 °C, 25 ml portions of the superna-
tant were frozen at -25 °C. Aprotinin (Trasylol®, Lot. No. 9011;
7139 KIU/mg polypeptide; Bayer AG, Wuppertal, Germany) was
dissolved in sterile saline (1 g/30 ml) and applied at a concentration
of 5 mg/kg.
Biochemical measurements
The following quantities were determined in citrated plasma,
bronchoalveolar lavage fluid or urine.
Sorbitol dehydrogenase3) according to 1. c. (21), lactate dehydroge-
nase3), creatinine, bilirubin and urea, using test combinations
(Boehringer, Mannheim, Germany). Total protein was determined
by the biuret method, albumin by the bromocresol green method
(22). Cell counting was performed in a Neubauer haemocytometer
after staining with Turk's solution. The chemiluminescence re-
sponse of citrated blood and isolated neutrophils was measured
according to previously described methods (19, 22, 23), in a six-
channel Biolumat LB 9505 (Berthold, Wildbad, Germany). Peak
maximum values of zymosan-induced photori emission (counts/
min· 25 000 neutrophils of isolated cell measurement; counts/rnin
• 250 000 neutrophils of blood measurement) were calculated as a
measure of the total metabolic capacity/activity, non-induced pho*
ton emission (spontaneous) as a measure of in vivo activation by
inflammatory mediators, and peak time values (min) as a measure
of the surface receptor expression on neutrophils. Urine aprotinin
concentration was measured according to 1. c. (24) and recalculated
as units (kallikrein inhibitor units, KJU).
2) Aprotinin (Trasylol®, Lot. No 9011; 7139 KIU/mg polypeptide)
was kindly provided by Dr. F. Schumann, Bayer AG, Wuppertal,
Germany
3) L-Iditol dehydrogenase (sorbitol dehydrogenase), Ζ,-Iditol :
NAD+ 5-oxidoreductase (EC 1.1.1.15)
Kininogenin (Kallikrein) (EC 3.4.21.8)
Lactate dehydrogenase, L-lactate : NAD+ oxidoreductase (EC
1.1.1.27)
Plasmin (EC 3.4.21.7)
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Statistics
Within- and between-group comparisons were performed on re-
peated measurements, using ANOVA ('STATISTICA' software
program) with post-hoc comparisons (Tukey's HSD test). Signifi-
cant within-group differences against baseline values are marked
in the figures by two asterisks if p < 0.05, while significant be-
tween group differences for corresponding time points are marked
by one asterisk if p < 0.05.
Data in the figures are presented as the mean and the standard error
of the mean (X ± SEM).
Results
Cardiac function and haemodynamics
The cardiac index increase for the control group became
significant at days 8—10, whereas cardiac index for the
aprotinin group remained in a normal range during the
total observation period. There were significant differ-
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Fig. l Cardiac index (a), systemic vascular resistance (b), and
mean arterial pressure (c) of multiple organ failure sheep in the
control group (ο; η = 10) and the aprotinin group (β; η = 6) in the
posttraumatic period.
Mean ± SEM; ** p < 0.05 values vs baseline; * p < 0.05 control
vs aprotinin group. Abscissa: time after haemorrhagic shock/intra-
medullary femoral nailing in days
Systemic vascular resistance decreased significantly for
the control group at days 7, 8 and 10, whereas there was
only an initial decrease of systemic vascular resistance
for the aprotinin group at day 2 with a complete recov-
ery till day 5 and with a constant level up to day 10
(fig. lb).
Mean arterial pressure increased for the control group
and remained unchanged for the aprotinin group. Be-
tween-group differences were significant at days 6,
8-10 (fig. Ic).
Pulmonary function
Pulmonary arterial oxygen tension fell constantly till
day 10 in both groups. There were significant differ-
ences between the groups at days 6 and 10 (fig. 2a).
Pulmonary vascular resistance increased till day 10 in
the control group, whereas there was no definite move-
ment in the aprotinin group. Significant differences be-
tween the groups were observed at day 8 (fig. 2b). Mean
pulmonary arterial pressure increased significantly at
days 7—10 in the control group, but did not change in
the aprotinin group during the total observation period.
Significant differences between the groups became obvi-
ous at days 3 — 10 (fig. 3a). The epithelial lining fluid/
plasma ratio of albumin concentrations increased signifi-
cantly after 6 and 10 days in the control group; there
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Fig. 2 Pulmonary arterial oxygen tension (a) and pulmonary vas-
cular resistance (b) of multiple organ failure sheep without (o) and
with (n) aprotinin therapy.
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Fig. 3 Mean pulmonary arterial pressure (a) and epithelial lining
fluid/plasma ratio (b) of albumin concentrations of multiple organ
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Fig. 4 Plasma sorbitol dehydrogenase activity (a) and plasma bi-
lirubin concentration (b) of multiple organ failure sheep without
(ο) and with (Ο) aprotinin therapy.
Liver function
After an initial reversible increase of the plasma sorbitol
dehydrogenase of control animals at day 1 there was a
late increase which became significant at day 9, whereas
aprotinin group values remained low for the total obser-
vation period. Between-group differences were signifi-
cant at day 10 (fig. 4a).
Plasma biiirubin concentrations in the control group in-
dicated an increase that became significant at days 9
and 10, whereas there was only a slight increase in the
aprotinin group. The differences »between the groups
were significant at days 8-10 (fig. 4b).
Kidney function
Creatinine clearance of the control group was normal till
day 5, then declined significantly at days 9 and 10,
whereas the aprotinin group indicated low values for the
total period; between group differences were significant
at day 5 (fig. 5a). The plasma urea concentration differed
only at day 10, in that the control group demonstrated
non-significantly higher values (fig. 5b). The daily total
amount of aprotinin eliminated with the urine peaked at
day 3 and then fell despite further aprotinin administra-
tion (fig. 6).
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Fig. 5 Creatinine clearance (a) and plasma urea concentration (b)
of multiple organ failure sheep without (o) and with (H) aprotinin
therapy.
0 1 2 3 4 5 6 7 8 9 1 0
Fig. 6 Urinary aprotinin excretion of trjultiple organ failure sheep
with aprotinin therapy.
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General cytoprotection
Plasma lactate dehydrogenase of the control group
increased significantly at day 10, whereas in the apro-
tinin group lactate dehydrogenase decreased steadily but
non-significantly from the first day onwards. There were
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Fig. 7 Plasma lactate dehydrogenase activity of multiple organ
failure sheep without (o) and with (n) aprotinin therapy.
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Neutrophil count and function in blood and
epithelial l ining fluid
Neutrophil count in blood increased significantly at day
10 for the control group and at days 6 and 9 for the
aprotinin group; significant differences between the
groups were observed at days 3, 6 and 7 (fig. 8a). Abso-
lute neutrophil count in epithelial lining fluid increased
significantly after 6 days for the control group, whereas
aprotinin goup values remained low (fig. 8b). Calcula-
tion of the releative portions of alveolar neutrophils
showed a significant increase after 6 and 10 days for the
control group (fig. 8c).
The chemiluminescence response to zymosan by neutro-
phils isolated from the blood demonstrated a nearly un-
changed course for the control group over the total ob-
servation period and a decrease of the aprotinin group
till day 6 with subsequent recovery; the difference at day
6 between the two groups was significant (fig. 9a). The
chemiluminescence response of neutrophils isolated
from the epithelial lining fluid showed a significant
decrease at day 6 for the control group, but there was
no significant difference between control and aprotinin
groups (fig. 9b). The chemiluminescence response dif-
ference of blood- and epithelial lining fluid-derived neu-
trophils (this difference indicates the loss of metabolic
capacity of neutrophils during their capillary-interstitial-
alveolar passage and is a measure of the amount of re-
active oxygen metabolites produced) increased signifi-
cantly at day 6 for the control group, and there was a
0 1 2 3 4 5 6 7 8 9 1 0
a t[d]
0 ,
Fig. 8 Neutrophil count in blood (a) and in epithelial lining fluid
(b and c) of multiple organ failure sheep without (o) and with (a)
aprotinin therapy.
^ 0 1 2 3 4 5 6 7 8 9 1 0
b t[d]
Fig. 9 Chemiluminescence response of blood-derived (a) and epi-
thelial lining fluid-derived (b) neutrophils of multiple organ failure
sheep without (o) and with (O) aprotinin therapy.
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significant difference between the two groups at day 6
(fig. 10). The spontaneous non-stimulated chemilumi-
nescence response, indicating the in vivo production and
stimulatory effect of inflammatory mediators, increased
for both groups, but was significantly higher for the con-
trol group at day 6 (fig. 11 a). The time taken to reach
the photon emission maximum, indicating neutrophilic
C3b receptor expression, decreased for the control group
and increased for the aprotinin group; there were signifi-
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Fig. 10 Difference of chemiluminescence response of blood- and
epithelial lining fluid-derived neutrophils of multiple organ failure
sheep without (o) and with (O) aprotinin therapy.
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Fig. 11 Spontaneous chemiluminescence of blood-derived neu-
trophils of multiple organ failure sheep without (o) and with (B)
aprotinin therapy (a) and time to reach the maximum of photon
emission response of blood-derived neutrophils of multiple organ
failure sheep without (o) and with (H) aprotinin therapy (b).
Discussion
Extensive neutrophil and endothelial cell activation and
interaction can result in the destruction of endothelial
and parenchymal structures, and in organ failure. Impor-
tant mediators of these reactions are reactive oxygen me-
tabolites and proteinases which can induce each other's
production, especially that of oxygen and nitric oxide
radicals by blood cascade system proteinases. This can
happen by direct or non-direct, i. e. complement-, fibri-
nolysis- or coagulations-associated reactions (fig. 12).
The main target enzymes of aprotinin, plasmin and
plasma kallikrein, are supposed to mediate neutrophil
and endothelial cell activation. Therefore, the inhibition
of these enzymes by aprotinin was expected to reduce
inflammatory mediator production below the level that
causes irreversible organ damage. To prove this assump-
tion, we used an animal model of multiple organ failure
which included the most important humoral and cellular
activation steps shown after multiple injuries in humans
(9, 10). In this model, sheep were subjected to haemor-
rhagic shock, intramedullary femoral nailing and re-
peated administration of endotoxin and zymosan-acti-
vated plasma for 5 d^ys. The animals of the control
group developed an irreversible sequential multiple or-
gan failure between 6 and 10 days, as was demonstrated
by monitoring the functional quantities of different or-
gans (10). By a simultaneous treatment with aprotinin
the significant alteration/impairment of several organ
functions could be avoided, resulting in the healing of
the experimentally induced multiple organ failure devel-
opment. Judged by different functional quantities, two
out of five organs/systems monitored demonstrated an
























ϋρο- Proteases Activation of the intrinsic blood coagulation system
poly- (contact system)
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Fig. 12 Inhibition by aprotinin of plasmin- and kallikrein-associ-
ated pathways.
EC = endothelial cell
ECa = activated endothelial cell
PMN = polymorphonuclear leukocyte
PMNa' = activated polymorphonuclear leukocyte
HMW kininogen = high molecular weight .kininogen
F XII = Hagemann factor .·
F XIIa = activated Hagemann factor
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Cardiac index, systemic vascular resistance and mean
arterial pressure indicated a significant normalisation of
cardiac function and haemodynamics.
Bilirubin as a marker of excretory and detoxicative liver
functions and sorbitol dehydrogenase as a marker of he-
patocyte membrane integrity indicated a significant im-
provement of liver function.
Furthermore, a general cytoprotective effect of aprotinin
presumably comprising all organs was observed by
measuring plasma lactate dehydrogenase.
Concerning the lung, there was no unique behaviour of
functional quantities. Three of them normalised with
aprotinin therapy (pulmonary vascular resistance, mean
pulmonary arterial pressure, epithelial lining fluid/
plasma ratio of albumin as a direct biochemical marker
of the lung capillary permeability damage (25)), whereas
one of them remained pathological (pulmonary arterial
oxygen tension). Therefore, the term 'improvement of
lung function' should be restricted to defined lung quan-
tities considered in this context.
The only organ without perceptible amelioration by
aprotinin was the kidney. Previously described renal ef-
fects of aprotinin (26) were also found in the depression
of the creatinine clearance for the total observation
period without tendency to improve. In contrast, Cum-
ming et al. found an aprotinin-induced improvement of
the renal function in an acute sheep model of septic
shock (18). This may be explained by the difference of
the models used. The plasma urea concentration fell
only insignificantly at day 10, and the aprotinin excre-
tion into the urine decreased from day 3 onwards, de-
spite continuous administration of aprotinin, indicating
the early impairment of the renal function.
The pathophysiology of this type of induced organ fail-
ure seems to be associated with neutrophil dysfunction
(3, 8, 27) and is assumed to be identical in different
organs. But, because of its unique anatomy, the lung
in particular offers the experimental design for easily
isolating and investigating neutrophils before (capillary
neütrophils) and after (alveolar neutrophils) they have
participated in the destructive processes of organ failure
during their capillary-interstitial-alveolar transition.
Thus, the increased alveolar influx of neutrophils, al-
ready previously observed (19, 28), indicated the partici-
pation of neutrophils, chemotaxins like IL-8 or C5a (29)
and reactive oxygen metabolites (30). This neutrophil
influx seemed to be reduced by the aprotinin-induced
inhibition of plasmin- and kallikrein-associated chemo-
taxin formation (fig. 12). The aprotinin-induced reduc-
tion of inflammatory mediator production was reflected
by the reduction of the spontaneous photon emission of
isolated neutrophils which had experienced less in vivo
priming by different amounts and/or types of inflamma-
tory mediators (31, 32). This was confirmed by the apro-
tinin-mediated reduction of in vivo neutrophil activation,
measured by the increase of the time taken to attain the
photon emission maximum of in vitro zymosan-acti-
vated neutrophils, representing a reciprocal measure of
in vivo C3b receptor expression by inflammatory media-
tor-induced activation (23).
The difference between the in vitro-induced reactive ox-
ygen metabolite production of simultaneously isolated
blood neutrophils and epithelial lining fluid neutrophils
was used as an index of lung tissue damage by neutro-
phils during their passage from the capillary into the
alveolus. For animals of the control group, which devel-
oped multiple organ failure, this difference was signifi-
cantly higher in comparison with aprotinin-treated ani-
mals which did not develop multiple organ failure.
The greater extent of control neutrophil priming by a
higher amount and/or more effective inflammatory me-
diators (as observed by the higher in vitro response of
control neutrophils) enables neutrophils in vivo and in
vitro to increase their reactive oxygen metabolite pro-
duction upon secondary stimulation and to produce a
higher degree of tissue damage. Since aprotinin prevents
the plasmin- and kallikrein-associated production of
priming inflammatory mediators, it contributes to the re-
duction of reactive oxygen metabolites produced by sec-
ondary stimulation and to the reduction of tissue de-
struction.
In summary, by the inhibition of plasmin- and kallikrein-
mediated pathways, aprotinin improved the function of
several injured organs, except kidney, and thus, pre-
vented at least partially the development of an experi-
mentally induced multiple organ failure in sheep.
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